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AbstrAct
Objective To create a mathematical model to investigate 
the treatment impact and economic implications of 
introducing an antimicrobial resistance point-of-care test 
(AMR POCT) for gonorrhoea as a way of extending the life 
of current last-line treatments.
Design Modelling study.
Setting England.
Population Patients accessing sexual health services.
Interventions Incremental impact of introducing a 
hypothetical AMR POCT that could detect susceptibility to 
previous first-line antibiotics, for example, ciprofloxacin 
or penicillin, so that patients are given more tailored 
treatment, compared with the current situation where 
all patients are given therapy with ceftriaxone and 
azithromycin. The hypothetical intervention was assessed 
using a mathematical model developed in Excel. The 
model included initial and follow-up attendances, loss 
to follow-up, use of standard or tailored treatment, time 
taken to treatment and the costs of testing and treatment.
Main outcome measures Number of doses of ceftriaxone 
saved, mean time to most appropriate treatment, mean 
number of visits per (infected) patient, number of patients 
lost to follow-up and total cost of testing.
Results In the current situation, an estimated 33 431 
ceftriaxone treatments are administered annually and 
792 gonococcal infections remain untreated due to loss 
to follow-up. The use of an AMR POCT for ciprofloxacin 
could reduce these ceftriaxone treatments by 66%, and 
for an AMR POCT for penicillin by 79%. The mean time for 
patients receiving an antibiotic treatment is reduced by 2 
days in scenarios including POCT and no positive patients 
remain untreated through eliminating loss to follow-up. 
Such POCTs are estimated to add £34 million to testing 
costs, but this does not take into account reductions 
in costs of repeat attendances and the reuse of older, 
cheaper antimicrobials.
Conclusions The introduction of AMR POCT could allow 
clinicians to discern between the majority of gonorrhoea-
positive patients with strains that could be treated with 
older, previously abandoned first-line treatments, and 
those requiring our current last-line dual therapy. Such 
tests could extend the useful life of dual ceftriaxone and 
azithromycin therapy, thus pushing back the time when 
gonorrhoea may become untreatable.
InTroducTIon
Increasing antimicrobial-resistant gonor-
rhoea represents a significant and urgent 
public health problem. Gonorrhoea, caused 
by Neisseria gonorrhoeae, is the second most 
commonly diagnosed bacterial sexually 
transmitted infection (STI) in England. N 
gonorrhoeae has evolved resistance to all major 
drug classes and has been recognised as a 
bacterium of international concern by WHO1 
and has been prioritised in the UK 5-year 
antimicrobial resistance (AMR) strategy.2
Diagnoses have more than doubled from 
16 839 in 2010 to 41 193 in 2015, mainly due 
to increased diagnoses in men who have sex 
with men (MSM), accounting for 70% of male 
infections in 2015, illustrated in figure 13 (data 
reported through GUMCADv2, including 
genitourinary medicine (GUM) clinics and 
other sexual health service providers, but 
Strengths and limitations of this study
 ► This study uses a simple framework to evaluate the 
potential impact of point-of-care tests to diagnose 
antimicrobial-resistant or antimicrobial-sensitive 
gonorrhoea infections.
 ► This study is parameterised with contemporary 
UK data on diagnoses, treatment and levels of 
antimicrobial resistance.
 ► This study uses a static model, so not possible to 
extrapolate future population effects.
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not general practice). Infections are often asymptomatic, 
especially in women and in pharyngeal and rectal infec-
tions in MSM, but are still transmissible.4 If untreated, 
complications of infection include pelvic inflammatory 
disease, infertility, increased risk of pregnancy compli-
cations and, in rare cases, life-threatening septicaemia.5 
Gonorrhoea infection also increases the risk of HIV 
acquisition.6
In the UK, the Gonococcal Resistance to Antimicrobial 
Surveillance Program (GRASP) has performed sentinel 
antibiotic susceptibility testing of gonorrhoea since 2000.7 
Increases in resistance to first-line therapies resulted in 
two changes in treatment recommendation (figure 1): 
from ciprofloxacin to cefixime in 2005 and then to ceftri-
axone plus azithromycin in 2011.7–9 Our current first-line 
therapy is also our last-line option, and while the use of 
dual therapy is intended to delay resistance developing 
to ceftriaxone, decreased susceptibility to either of these 
drugs could lead to untreatable infections. While new 
antibiotics are in development, their use in the clinic may 
be many years away and already the world’s first reported 
clinical treatment failure with confirmed ceftriaxone and 
azithromycin resistance has occurred.7
There are two main challenges to the management of 
gonorrhoea which contribute to the problem of resis-
tance, illustrated in figure 2. (1) Precautionary treatment: 
at the time of diagnosis all infections are treated as if they 
are resistant to older antibiotics; and (2) epidemiological 
treatment: sexual contacts of gonorrhoea cases are often 
treated before diagnostic test results are known, resulting 
in unnecessary treatment of uninfected partners. The 
cornerstone of gonorrhoea management to date has 
been to ensure rapid, highly effective treatment is given 
to prevent the onward spread of infection to sexual part-
ners and to prevent people not returning for treatment 
following a diagnosis. In the context of antibiotic resis-
tance and new diagnostic technologies, it is necessary to 
reassess these priorities.
Strategies are required to extend the life of existing anti-
microbials for the successful treatment of gonorrhoea. 
Most infections diagnosed in the UK are susceptible to 
cefixime, ciprofloxacin and even penicillin.7 Therefore, 
if a point-of-care test (POCT) could be developed to 
test for resistance (or susceptibility) to antibiotics, most 
Figure 1 Number of gonorrhoea diagnoses reported in 
England, 2006–2015, with the change in recommended 
first-line antibiotic treatment shown. Data from Public Health 
England, Annual STI Data Tables (https://www.gov.uk/
government/statistics/sexually-transmitted-infections-stis-
annual-data-tables). MSM, men who have sex with men.
Figure 2 Current patient pathways for gonorrhoea. AMR, antimicrobial resistance.
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patients could be treated with an older oral first-line 
therapy, potentially extending the life of ceftriaxone 
as our last-line therapy.10 A promising option based on 
existing nucleic acid amplification test (NAAT) could be 
a PCR test for ciprofloxacin resistance, using the gyrA 
gene as a target.10 11 Other technologies could involve 
direct measurement of live cell responses to the presence 
of a panel of antibiotics including microfluidic devices, 
atomic force microscopy, volatile chemical detection or 
mass spectroscopy. Computational approaches based on 
in silico phenotyping based on genotype may also be able 
to detect new mutations more rapidly than traditional 
microbiological testing.12–14 In this study, we developed a 
mathematical model to investigate the treatment impact 




We developed a decision tree model in Excel to consider 
the impact of a hypothetical new AMR POCT on testing, 
diagnosis and treatment of gonorrhoea in sexual health 
clinics in England (figure 3) compared with current 
practice. Genitourinary clinics typically triage attending 
patients based on whether they have symptoms or report 
Figure 3 Patient pathway diagram to illustrate the flow for men who have sex with men (MSM) under (A) current care and (B) 
antimicrobial resistance (AMR) point-of-care test (POCT). In scenario A, all diagnosed cases are treated with ceftriaxone plus 
azithromycin. In scenario B, diagnosed cases are treated according to resistance profile: AMR cases with ceftriaxone plus 
azithromycin; non-AMR with ciprofloxacin. Numbers of AMR and non-AMR infection are based on current levels of ciprofloxacin 
resistance observed in Gonococcal Resistance to Antimicrobial Surveillance Program surveillance data, 2014. Illustrated based 
on 100 000 MSM attending a genitourinary medicine clinic.
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contact with a sexual partner infected with a specific 
infection (‘same day management’) and those without 
symptoms (‘delayed management’) where treatment is 
delayed until the results of diagnostic tests are returned 
from the laboratory (2–7 days) (figure 2). Current prac-
tice is therefore a mixture of same day management and 
delayed management depending on clinic patient mix. 
Guidelines recommend that patients treated for gonor-
rhoea also have swabs taken at the time of treatment that 
are sent for susceptibility testing, but these results are 
not available until after treatment has been given. The 
alternative strategy is based on a point-of-care gonor-
rhoea diagnostic test for all patients. The POCT could be 
either a simple diagnostic for gonorrhoea (infected/not 
infected) or a test which can discriminate between one 
specific resistance/susceptibility determinants (POCT 
AMR). Simple POCT tests are commercially available and 
have been piloted in clinic15 but POCT AMR tests are 
still in development. More complex testing algorithms 
and diagnostic technologies could be envisioned, for 
example, only using an AMR POCT if the initial simple 
POCT is positive (reflex testing) or using more complex 
algorithms and new technologies to determine optimal 
treatment options. In this preliminary example, we 
consider two options of antimicrobial susceptibility: (1) 
ciprofloxacin and (2) penicillin.16 17
The model was based on an existing pathway model 
used to investigate the impact of introducing a dual 
POCT for gonorrhoea and chlamydia in a GUM 
setting,17 18 but simplified in that onward transmission of 
gonorrhoea and partner notification were not included, 
with the focus being on diagnosis and tailored treatment, 
shown in figure 3 for MSM patient group (corresponding 
pathways for heterosexual men and women are given in 
the online supplementary appendix figure A1A-D). We 
explicitly included branches to differentiate susceptible 
and resistant isolates within the pathway framework. For 
the purpose of our study, we assumed that all POCTs have 
equivalent sensitivity and specificity to current PCR labo-
ratory tests. Previous models have considered variable 
specificity and sensitivity requirements in more detail.16
Hypothetical cohorts of patients were followed through 
the pathway (MSM, heterosexual men and heterosexual 
women). Individuals could either receive same day 
management or delayed management (figure 3) under 
current practice or for POCT pathway all patients are 
assumed tested, diagnosed and treated on the same day. 
The only difference between POCT and AMR POCT is 
therefore in the choice of antimicrobial therapy. Treat-
ments modelled were either our current last-line dual 
therapy of ceftriaxone and azithromycin (current pathway 
or simple POCT) or in the case of scenarios including 
AMR POCT a proportion of patients were provided with 
either ciprofloxacin or penicillin, plus azithromycin 
co-therapy, as an alternative regimen where possible. Loss 
to follow-up when patients were recalled for treatment 
following laboratory testing to determine positivity for 
gonorrhoea was explicitly included for current pathway 
only. We assumed that results of point-of-care diagnos-
tics can be provided within the clinical consultation, 
for example, if patients provide samples for testing on 
arrival at a GUM clinic and then wait for an appointment 
or return later in the day. It is possible that this would 
result in delays to treatment for symptomatic individuals 
and sexual contacts, but we do not consider this further.
Parameter values
Full model parameters are provided in the online supple-
mentary appendix tables A1 and A2. Estimates of the 
numbers of patients attending GUM clinics and tested 
for and diagnosed with gonorrhoea were based on 
recent data from Public Health England (PHE).19 The 
model is run assuming 515 094 MSW, 145 863 MSM and 
779 085 women attend a GUM clinic in 201419 and the 
proportions entering same day management or who are 
infected adjusted to generate the observed diagnoses of 
gonorrhoea in each group. In 2014, there were >33 000 
diagnoses of gonorrhoea reported by PHE, just over half in 
MSM and the remaining heterosexual cases split roughly 
equally between men and women. We combined data on 
patients presenting as contacts of gonorrhoea cases or 
with symptoms into the ‘same day management’ pathway. 
Asymptomatic patients were tested, but treatment was 
assumed to be delayed until the results of laboratory tests 
were known. We distributed infected patients between 
the pathways according to specific parameters for each 
patient group based on the probability of being infected 
and the likelihood of having symptoms. Symptomatic 
patients are more likely to be managed on the same day 
as testing and heterosexual men (MSW) are the most 
likely to be symptomatic, followed by MSM, then women. 
(Data from the Maximising STI Control trial, personal 
communication Cath Mercer) (table 1).17 18 20 These 
parameters were informed by national PHE data where 
available and supplemented with additional data or clin-
ical experience and are described fully elsewhere.17 20 
The difference between MSM and MSW may be due to 
a combination of factors including higher probability 
of extragenital infection, higher incidence of repeat 
infections and higher probability of HIV coinfection 
and higher frequency of STI testing in this group.21 We 
estimated the proportions of infections that are resis-
tant to ciprofloxacin and/or penicillin from the GRASP 
2014 report (online supplementary appendix table A1), 
which included systematic susceptibility testing at the 
PHE reference laboratory from sentinel surveillance 
sites and a larger but less well-defined analysis of samples 
tested locally.22 Parameters were varied to be appro-
priate to three patient groups: heterosexual men, MSM 
and women. In the baseline case, we assumed that all 
confirmed and presumptive gonorrhoea infections are 
treated with ceftriaxone and azithromycin because there 
is >5% resistance to alternative regimens, resulting in 
100% of infections treated as if they are resistant to other 
antibiotics (such as ciprofloxacin). The cost for patients 
attending GUM was taken from the latest payment by 
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results tariff.23 An AMR POCT is not currently available 
so we assumed conservatively that separate new tests for 
assessing resistance to either ciprofloxacin or penicillin 
would each incur an additional £25 testing cost, similar 
to that previously assumed for a PCR-based POCT test.17
Management scenarios
We considered the following scenarios for each of the 
three patient groups (MSM, heterosexual men and 
women).
1. Current management: Clinicians have no knowledge 
of the resistance profile of gonorrhoea at the point 
of initial treatment and consequently all patients are 
treated with ceftriaxone and azithromycin. Some 
patients are managed on the same day, either due 
to symptoms and positive microscopy or as contacts 
of infected individuals, others wait for lab results, 
resulting in some unnecessary treatment and some 
delays to treatment or loss to follow-up (figure 2).
2. Simple POCT management: All patients tested and 
managed same day but all treated as if resistant to 
older antibiotics (ie, ceftriaxone and azithromycin).
3. AMR POCT management: All patients tested with 
AMR POCT for gonorrhoea that could identify 
infections that do not need to be treated with 
ceftriaxone
a. assuming current ciprofloxacin resistance 
prevalence22 (figure 2).
b. assuming current penicillin resistance 
prevalence.22
economic analysis
The primary outcomes were the number of doses of 
ceftriaxone saved and the mean time to appropriate 
treatment. In addition, we calculated the average 
number of visits per person and per infected person, the 
total cost of testing and the number of patients lost to 
follow-up. In each case, we compared the incremental 
Table 1 Principal results comparing use of an antimicrobial resistance point-of-care test (AMR POCT) for ciprofloxacin 
(scenario 3a) or penicillin resistance (scenario 3b) against current testing practice (standard laboratory testing, no POCT) for the 
management of gonorrhoea (scenario 1), assuming the current attendance at genitourinary medicine clinic annually
Heterosexual 
male MSM Female Overall
Considering use of POCT test for ciprofloxacin resistance
Annual ceftriaxone treatments
  Current (scenario 1) 7690 17 691 8050 33 431
  AMR POCT (scenario 3a) 2188 7933 1257 11 378
  Reduction under scenario 3a 5502 9759 6793 22 054
  Percentage reduction in ceftriaxone 72 55 84 66
Proportion treated same day (%)
  Current (scenario 1)  68 63 21 54
  AMR POCT (scenario 3a)  100 100 100 100
  Increase under scenario 3a  32 37 79 46
Mean time to treatment (days)
  Current (scenario 1) 1.5 1.8 3.9 2.2
  AMR POCT (scenario 3a) 0.0 0.0 0.0 0.0
  Reduction under scenario 3a 1.5 1.8 3.9 2.2
Persons lost to follow-up (untreated)
  Current (scenario 1) 125 338 329 792
  AMR POCT (scenario 3a) 0 0 0 0
Considering use of POCT test for penicillin resistance
Annual ceftriaxone treatments*
  Current (scenario 1) 7690 17 691 8050 33 431
  AMR POCT (scenario 3b) 1407 4688 838 6932
  Reduction under scenario 3b 6283 13 004 7212 26 499
  Percentage reduction in ceftriaxone 82 74 90 79
*All other outcomes same as for use of POCT for ciprofloxacin resistance. Results for strategy 2 not shown: equivalent to strategy 3 except 
for choice of antibiotic treatment. Results for 3b also equivalent to 3a for outcomes except reduction in ceftriaxone treatments.
MSM, men who have sex with men.
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benefit of an AMR POCT with current testing practice. 
Analyses were undertaken from the National Health 
Service perspective with costs measured in pounds ster-
ling at 2014 prices.
resulTs
We modelled a snapshot of GUM attendance, gonor-
rhoea diagnosis and prevalence of resistance to 
ciprofloxacin and penicillin based on the situation in 
England, 201419. Under current treatment guidelines for 
1.4 million people attending GUM per year, we estimate 
33 431 ceftriaxone treatments are currently adminis-
tered annually and 792 gonococcal infections remain 
untreated due to loss to follow-up. In those receiving 
antibiotics, the mean time to treatment was estimated 
to be 2.2 days. Under current practice, 68% (MSW), 
63% (MSM) and 21% (women) who are infected with 
gonorrhoea are treated on the same day as they attend. 
The mean number of attendances at clinic per infected 
person was 1.44. We estimated the total cost of current 
testing to be £196 million. If a POCT test is used (strat-
egies 2–4), this enables same day testing and treatment, 
patients would only need to visit once, all infected indi-
viduals would be treated on the same day as the test 
and therefore no infected individuals would be lost to 
follow-up and left untreated.
The results for AMR POCT (strategies 3 and 4) and 
POCT (strategy 2) only differ by the choice of treatment 
regimen. If an AMR POCT for ciprofloxacin resistance 
were available (strategy 3a), we estimate its use could 
prevent 22 054 treatments of ceftriaxone annually (a 
66% reduction) assuming the current levels of resis-
tance to ciprofloxacin (37% of infections in 2014,24 
table 1). Similarly, an AMR POCT for penicillin resis-
tance (strategy 3b) at the current levels of resistance 
(23% overall) could prevent 26 499 ceftriaxone treat-
ments annually (a 79% reduction). Assuming an AMR 
POCT added £25 to the testing costs, we estimated the 
total cost of testing for each of the POCT scenarios to 
be £230 million, adding £34 million to the annual cost of 
testing (table 2).
dIscussIon
statement of principal findings
Our model estimates that 66% of the 33 431 ceftriaxone 
treatments given annually to individuals with gonorrhoea 
could be replaced by ciprofloxacin, thus extending the 
life of our current last-line treatment, if an AMR POCT 
for ciprofloxacin resistance was available. If an AMR 
POCT for penicillin was available, 79% of ceftriaxone 
treatments could be substituted with penicillin. The use 
of POCTs would mean a 2-day reduction in the time 
that people wait, on average, for appropriate treatment 
compared with current practice and such testing would 
prevent the approximately 800 positive individuals who 
remain untreated in the current system due to loss to 
follow-up. If AMR POCT added £25 to first-line testing 
costs, we estimate the use of such tests would increase 
current treatment and testing costs by £34 million annu-
ally. The outcomes related to same day diagnosis and 
treatment (reduced time to treatment and reduced 
follow-up) could be achieved by using a simple POCT, as 
previously considered.17 The additional benefit of AMR 
POCT test is to enable tailored choice of antimicrobial 
treatment.
strengths and weaknesses of the study
Our model used recent published data on AMR levels, 
gonococcal incidence and current treatment and consid-
ered the impact of additional AMR POCT in distinct 
population groups, namely heterosexual men, MSM 
and females. The simplified model structure, which is 
available freely online, enables the parameters to be 
easily updated and the impact of different scenarios, in 
different settings, to be considered. We made the simpli-
fying assumption that the cost of an AMR POCT would 
add £25 to the current tariff cost; however, in reality other 
current activities might be reduced or discontinued if an 
AMR POCT was available, such as testing, microscopy, 
culture and physical exams or reattendances, as well as 
reduced costs associated with reusing cheaper oral antibi-
otics. New DNA-based POCT technologies may be able to 
be combined to produce a multiplexed test, which may be 
more economically viable than the separate specific AMR 
tests we modelled here. Our cost estimates are therefore 
Table 2 Cost of testing and treatment* when using an antimicrobial resistance point-of-care test (AMR POCT) for 
ciprofloxacin resistance (strategy 3a) compared with current practice
Heterosexual male MSM Female Overall
Annual cost of testing (£)
  Current 69 784 517 20 358 694 105 826 467 195 969 677
  AMR POCT 82 415 040 23 338 080 124 653 600 230 406 720
  Increased cost with AMR POCT 12 630 523 2 979 386 18 827 133 34 437 043
*The model assumes that the additional cost of AMR POCT (£25) is simply added to the cost of attendance and is not offset by reductions in 
the number of gonorrhoea infections by reduced treatment costs (as some patients are treated with cheaper antibiotics),or by reduced use of 
other tests (such as microscopy or culture of all swabs).
MSM, men who have sex with men.
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likely to be higher than in practice. New technologies are 
emerging that may be able to rapidly determine the bacte-
rial response to a panel of potential antibiotics which 
would enable highly tailored therapy without the need to 
continuously monitor the efficacy of a test for resistance 
based on detecting DNA sequence, but for this prelimi-
nary exploration we selected a hypothetical AMR POCT 
test which could integrate with existing POCT technolo-
gies based on nucleic acid amplification.
The model did not capture the indirect effects of 
reduced transmission to partners or progression to 
complications, such as pelvic inflammatory disease and 
epididymitis. It also did not consider the longer-term 
effects of changing treatment strategy on the evolution of 
drug resistance over time in gonorrhoea infections.
strengths and weaknesses in relation to other studies, 
discussing important differences in results
To our knowledge, no one has specifically addressed 
the question of the added value of an AMR POCT to 
discriminate between susceptible and resistant strains to 
guide initial treatment decisions for gonorrhoea. Others 
have considered in detail the relative benefits of POCTs, 
balancing the need for fast results against cost and test 
performance.16 Adams et al previously showed that a 
dual chlamydia/gonorrhoea point-of-care NAAT diag-
nostic test pathway could be cost-neutral or cost-saving 
compared with existing methods even though the test kit 
itself is more expensive.17 18 We initially assumed that the 
POCT AMR is an additional test cost; however, it is prob-
able that a multiplex PCR rapid test could be designed to 
include an AMR component which does not compromise 
the cost or performance of the basic gonorrhoea diag-
nostic. An alternative to improving diagnostics, treatment 
and surveillance is to develop a vaccine for gonorrhoea 
and to improve the uptake of other methods of preven-
tion (such as condoms).25 26 A gonorrhoea vaccine has 
proved elusive due to the rapidly changing surface anti-
gens, but there may be some cross-reactivity with vaccines 
designed to protect against Neisseria meningitidis.27
The main weakness of our study is that it did not 
address the population-level impact of the introduction 
of such tests, but only considered a static situation.24 25 28 
Rapid whole-genome sequencing (within 24 hours) has 
been introduced to help guide treatment decisions for 
important nosocomial pathogens, notably methicillin-re-
sistant Staphylococcus aureus,14 but in a community walk-in 
clinic setting for a low-prevalence bacterial infection, 
such as gonorrhoea, a test needs to be relatively cheap 
and results available before the patient leaves the clinic. 
Our model did not include dynamic epidemiological 
or evolutionary processes, which change the prevalence 
and incidence of infection (and resistance) over time.24 
In reality, reintroduction of ciprofloxacin would likely 
increase the selection for resistance, which would negate 
some of the benefits of an AMR POCT. Similarly, reusing 
other drugs would also result in increases in resistance 
observed, including increasing selection for plasmids 
conferring multidrug resistance. Conversely, if point-of-
care technology can reduce the time to treatment and 
reduce loss to follow-up sufficiently this might reduce 
the overall population prevalence, which would lead to 
a virtuous cycle of improved control and reduced trans-
mission risk.29 We also assume that results of point-of-care 
diagnostics can be provided within the clinical consul-
tation. This is not currently possible unless the patient 
provides samples on arrival then waits to see a clinician or 
returns for a later appointment. The Cepheid GeneXpert 
has a turnaround time of about 90 min which was previ-
ously found to result in the majority of men (16/19) not 
waiting for their results (six were positive).30 Transmission 
dynamic models can explore the potential consequences 
without the risks associated with radical changes in 
prescribing practices. The next steps will be to develop 
dynamic models which include selective pressure under 
differing treatment options31 and incorporating variable 
delays.
The important next questions arising from this 
study are: how much time does the reduction in use of 
ceftriaxone buy in terms of slowing or preventing the 
emergence of clinically relevant gonorrhoea resistant to 
ceftriaxone and, second, what are the population-level 
benefits of improved gonorrhoea control?
Meaning of the study: possible explanations and 
implications for clinicians and policymakers
The major benefit of POCTs for gonorrhoea is increasing 
the proportion of patients treated appropriately on the 
same day as the test, which is likely to improve outcomes 
by reducing infectious duration, reducing loss to follow-up 
and potentially improving partner notification efficacy. A 
definitive diagnosis on the day of first presentation also 
prevents unnecessary treatment of those not infected 
with gonorrhoea. The main benefit of an AMR POCT 
that can discriminate between susceptible and resistant 
infections is in enabling the reintroduction of abandoned 
first-line therapies. Reducing the use of antibiotics, espe-
cially of last-line therapies, is a key aim of the UK national 
strategy on AMR. For heterosexual men and MSM, a rela-
tively large proportion of infections are already treated 
on the same day as testing, based on epidemiological, 
clinical or microbiological evidence (microscopy). 
However, this proportion is lower for women due to the 
higher percentage of asymptomatic infections and from 
poorer sensitivity of detection of gonorrhoea in endocer-
vical and urethral smears. Although new POCTs are likely 
to be more expensive than existing tests, this would to 
some extent be offset by the reduction in further atten-
dances and in the ability to reuse older, cheaper drugs. 
Given the low prevalence of gonorrhoea even in high-risk 
GUM attendees, the cost of treatment and reattendances 
is small in comparison with the cost of attendances for 
testing and diagnosis. If a new discriminatory AMR POCT 
test were prohibitively expensive for routine use, a combi-
nation of a standard point-of-care NAAT (eg, chlamydia/
gonorrhoea) could be considered in conjunction with 
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a more specialised gonorrhoea AMR test, although the 
time implications of this for patients and clinicians would 
have to be carefully considered.
unanswered questions and future research
This estimation of the potential reduction in ceftriaxone 
use is the first step towards evaluating the long-term 
effects of such a reduction. Future research investigating 
how much the useful lifespan of ceftriaxone as a therapy 
for gonorrhoea is extended with particular reductions in 
ceftriaxone use would be valuable. In the context of the 
often slow and expensive new drug pipeline, there is also 
a question to be answered around the value placed on 
each additional year of ceftriaxone availability.
Author affiliations
1School of Veterinary Sciences, University of Bristol, Langford House, Bristol, UK
2School of Social and Community Medicine, University of Bristol, Oakfield House, 
Oakfield Grove, Bristol, UK
3Aquarius Population Health, London, UK
4Duke Fuqua School of Business, Durham, USA
5Bacteriology Reference Department, National Infection Service, Public Health 
England, London, UK
6The O’Neill Review on Antimicrobial Resistance, Wellcome Trust, London, UK
Acknowledgement The authors acknowledge Lord Jim O’Neill, chairman of the 
Review on Antimicrobial Resistance and the review team, for commissioning the 
study.
Contributors All authors were involved in the conception and design of the 
research. KT, EA and HC developed the models, following initial work by DM and 
NW and based on previous published work by EA and KT. KT and HC analysed the 
model results and all authors interpreted the results. HF and NW provided input into 
current clinical practice relating to AMR. KT, HC and NW wrote the first draft of the 
manuscript. All authors drafted the final version of the manuscript. All authors had 
full access to all of the data in the study and can take responsibility for the integrity 
of the data and the accuracy of the data analysis.
Funding  KT was funded by BristolBridge (grant number EP/M027546/1) under 
the EPSRC Bridging the Gaps between the Engineering and Physical Sciences and 
Antimicrobial Resistance cross-council AMR initiative. The model was developed 
from published work previously funded by Aquarius Population Health. 
Disclaimer The views expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR, the Department of Health or Public Health England. 
Competing interests KT reports personal fees from Aquarius Population Health, 
other from WHO, grants from Guys and St Thomas Charity , outside the submitted 
work; and is an editor of Sexually Transmitted Infections. HC reports grants from 
NIHR, during the conduct of the study; other from Sanofi Pasteur, outside the 
submitted work. HC was funded by the NIHR Protection Research Unit (NIHR HPRU) 
in Evaluation of Interventions at the University of Bristol in partnership with Public 
Health England (PHE). EA reports no compensation for the submitted work, and 
grants from Cepheid, Atlas Genetics, St Georges University of London, Enigma 
Diagnostics and AstraZeneca, outside the submitted work. AM reports personal 
fees from Department of Health, non-financial support from Wellcome Trust, 
outside the submitted work. NW reports PHE’s AMRHAI Reference Unit receiving 
financial support from Achaogen Allecra Antiinfectives , Amplex, AstraZeneca 
UK, Becton Dickinson Diagnostics, BSAC, Cepheid, Check-Points B.V., Cubist 
Pharmaceuticals, Department of Health, Enigma Diagnostics, Food Standards 
Agency, GlaxoSmithKline Services, Henry Stewart Talks, IHMA, Merck Sharpe & 
Dohme, Meiji Seika Kiasya, Momentum Biosciences, Nordic Pharma , Norgine 
Pharmaceuticals, Rempex Pharmaceuticals, Rokitan, Smith & Nephew UK , Trius 
Therapeutics, VenatoRx and Wockhardt, outside the submitted work. 
Patient consent No patient data used in this study except nationally published 
aggregate figures from PHE.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Details of the model data inputs and other assumptions 
are provided in the methods and supporting parameters table. The model is 
available from http:// amr- review. org/ file/ 429 and researchers interested in further 
details may contact the corresponding author at  katy. turner@ bristol. ac. uk.
Open Access This is an Open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits 
others to distribute, remix, adapt and build upon this work, for commercial use, 
provided the original work is properly cited. See: http:// creativecommons. org/ 
licenses/ by/ 4.0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
references
 1. WHO. Antimicrobial resistance global report on surveillance: 2014 
summary, 2014.
 2. Health UGDo. UK five year antimicrobial resistance Strategy 2013 to 
2018, 2011.
 3. Public Health England. STI diagnoses & rates by gender, sexual risk & 
age group, 2011 - 2015, 2016.
 4. Korenromp EL, Sudaryo MK, de Vlas SJ, et al. What proportion of 
episodes of gonorrhoea and Chlamydia becomes symptomatic? Int J 
STD AIDS 2002;13:91–101.
 5. Yeh JM, Hook EW, Goldie SJ. A refined estimate of the average 
lifetime cost of pelvic inflammatory disease. Sex Transm Dis 
2003;30:369–78.
 6. Chesson HW, Pinkerton SD. Sexually transmitted diseases and 
the increased risk for HIV transmission: implications for cost-
effectiveness analyses of sexually transmitted disease prevention 
interventions. J Acquir Immune Defic Syndr 2000;24:48–56.
 7.  Public Health England. 2016. GRASP Report 2016.
 8. Bignell C, Fitzgerald M, Guideline Development G. British Association 
for Sexual H, Hiv UK. UK national guideline for the management of 
gonorrhoea in adults, 2011. Int J STD AIDS 2011;22:541–7.
 9. Public Health England GRASP Steering Committee and BASHH 
CEG. Gonorrhoea Treatment Position Statement, 2015.
 10. Hemarajata P, Yang S, Soge OO, et al. Performance and Verification 
of a Real-Time PCR assay targeting the gyrA Gene for prediction of 
Ciprofloxacin Resistance in Neisseria gonorrhoeae. J Clin Microbiol 
2016;54:805–8.
 11. Chaudhry U, Ray K, Bala M, et al. Mutation patterns in gyrA 
and parC genes of ciprofloxacin resistant isolates of Neisseria 
gonorrhoeae from India. Sex Transm Infect 2002;78:440–4.
 12. De Silva D, Peters J, Cole K, et al. Whole-genome sequencing to 
determine transmission of Neisseria gonorrhoeae: an observational 
study. Lancet Infect Dis 2016;16:1295–303.
 13. Allen VG, Melano RG. Whole-genome sequencing-new tools for 
gonorrhoea control. Lancet Infect Dis 2016;16:1214–5.
 14. Aanensen DM, Feil EJ, Holden MT, et al. European SRL Working 
Group. Whole-Genome sequencing for routine pathogen surveillance 
in Public Health: a Population Snapshot of Invasive Staphylococcus 
aureus in Europe. MBio 2016;7:e00444-16.
 15. Harding-Esch EM, Nori AV, Hegazi A, et al. Impact of deploying 
multiple point-of-care tests with a 'sample first' approach on a sexual 
health clinical care pathway. A service evaluation. Sex Transm Infect 
2017.
 16. Vickerman P, Watts C, Alary M, et al. Sensitivity requirements for 
the point of care diagnosis of Chlamydia trachomatis and Neisseria 
gonorrhoeae in women. Sex Transm Infect 2003;79:363–7.
 17. Turner KM, Round J, Horner P, et al. An early evaluation of clinical 
and economic costs and benefits of implementing point of care 
NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea 
in genitourinary medicine clinics in England. Sex Transm Infect 
2014;90:104–11.
 18. Adams EJ, Ehrlich A, Turner KM, et al. Mapping patient pathways 
and estimating resource use for point of care versus standard 
testing and treatment of Chlamydia and gonorrhoea in genitourinary 
medicine clinics in the UK. BMJ Open 2014;4:e005322.
 19. Public Health England. STI diagnoses & rates by gender, sexual risk & 
age group, 2010 - 2014, 2015.
 20. Mercer CH, Macdonald N, Shirley MDF, et al. The Maximising STI 
Control (MSTIC) webtool: a new approach to facilitate the planning of 
services for sexually transmitted infections to maximise public health 
benefit. The Lancet 2013;382:S6.
 21. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and 
pharyngeal Chlamydia and gonorrhea detected in 2 clinical settings 
among men who have sex with men: San Francisco, California, 2003. 
Clin Infect Dis 2005;41:67–74.
group.bmj.com on June 16, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 9Turner KME, et al. BMJ Open 2017;7:e015447. doi:10.1136/bmjopen-2016-015447
Open Access
 22. Public Health England. Surveillance of antimicrobial resistance 
in Neisseria gonorrhoeae. Key findings from the ‘Gonococcal resistance 
to antimicrobials surveillance programme' (GRASP) and related 
surveillance data, 2014.
 23. Monitor and NHS England. National tariff payment system 2014/15, 
2013.
 24. Grad YH, Goldstein E, Lipsitch M, et al. Improving control of 
Antibiotic-Resistant gonorrhea by Integrating Research Agendas 
across Disciplines: key questions arising from mathematical 
modeling. J Infect Dis 2016;213:883–90.
 25. Garnett GP. The theoretical impact and cost-effectiveness of 
vaccines that protect against sexually transmitted infections and 
disease. Vaccine 2014;32:1536–42.
 26. Régnier SA, Huels J. Potential impact of vaccination against 
Neisseria meningitidis on Neisseria gonorrhoeae in the United States: 
results from a decision-analysis model. Hum Vaccin Immunother 
2014;10:3737–45.
 27. Whelan J, Kløvstad H, Haugen IL, et al. Ecologic Study of 
meningococcal B vaccine and Neisseria gonorrhoeae infection, 
Norway. Emerg Infect Dis 2016;22:1137–9.
 28. O'Neill J. Tackling Drug-Resistant infections globally: final report and 
recommendations. The review on antimicrobial resistance 2016.
 29. White PJ, Ward H, Cassell JA, et al. Vicious and virtuous circles in 
the dynamics of infectious disease and the provision of health care: 
gonorrhea in Britain as an example. J Infect Dis 2005;192:824–36.
 30. Harding-Esch EM, Hegazi A, Okolo O, et al. P2.163 Do “In-
Clinic” Molecular and Non-Molecular Rapid Tests Improve Patient 
Management?. Sex Transm Infect 2013;89:A137.3–A138.
 31. McAdams D. Resistance diagnosis and the changing epidemiology 
of antibiotic resistance. Ann N Y Acad Sci 2017;1388:5–17.
group.bmj.com on June 16, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
: a modelling studygonorrhoeae
Neisseriaand susceptible strains of 
infections caused by antimicrobial-resistant
to enable individualised treatment of 
Analysis of the potential for point-of-care test
McAdams, Helen Fifer, Anthony McDonnell and Neil Woodford
Katy ME Turner, Hannah Christensen, Elisabeth J Adams, David
doi: 10.1136/bmjopen-2016-015447
2017 7: BMJ Open 
 http://bmjopen.bmj.com/content/7/6/e015447




This article cites 21 articles, 9 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections




To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on June 16, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
